BACKGROUND: Premature infants are at increased risk for metabolic bone disease, with resulting delayed bone growth, osteopenia, and rickets. METHOD: A systematic review of the best available evidence to answer a series of questions regarding neonatal patients at risk of metabolic bone disease receiving parenteral or enteral nutrition was undertaken and evaluated using concepts adopted from the Grading of Recommendations, Assessment, Development and Evaluation working group. A consensus process was used to develop the clinical guideline recommendations prior to external and internal review and approval by the American Society for Parenteral and Enteral Nutrition Board of Directors. QUESTIONS: (1) What maternal risk factors predispose the neonate to metabolic bone disease? (2) What is the optimal type of feeding to promote neonatal bone health? (3) When and how should vitamin D supplements be administered? (4) Does parenteral nutrition (PN) predispose a neonate to metabolic bone disease, and if so, are there PN formulation recommendations to minimize this risk?
BACKGROUND: Premature infants are at increased risk for metabolic bone disease, with resulting delayed bone growth, osteopenia, and rickets. METHOD: A systematic review of the best available evidence to answer a series of questions regarding neonatal patients at risk of metabolic bone disease receiving parenteral or enteral nutrition was undertaken and evaluated using concepts adopted from the Grading of Recommendations, Assessment, Development and Evaluation working group. A consensus process was used to develop the clinical guideline recommendations prior to external and internal review and approval by the American Society for Parenteral and Enteral Nutrition Board of Directors. QUESTIONS: (1) What maternal risk factors predispose the neonate to metabolic bone disease? (2) What is the optimal type of feeding to promote neonatal bone health? (3) When and how should vitamin D supplements be administered? (4) Does parenteral nutrition (PN) predispose a neonate to metabolic bone disease, and if so, are there PN formulation recommendations to minimize this risk?
Authors: Roland N Dickerson; Vanessa J Kumpf; Carol J Rollins; Eric H Frankel; Michael D Kraft; Todd W Canada; Catherine M Crill Journal: Hosp Pharm Date: 2014-09
Authors: Per T Sangild; Denise M Ney; David L Sigalet; Andreas Vegge; Douglas Burrin Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-10-23 Impact factor: 4.052
Authors: Robert K Huston; J Mark Christensen; Sultan M Alshahrani; Sumeia M Mohamed; Sara M Clark; Jeffrey A Nason; Ying Xing Wu Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: William B Grant; Spyridon N Karras; Heike A Bischoff-Ferrari; Cedric Annweiler; Barbara J Boucher; Asta Juzeniene; Cedric F Garland; Michael F Holick Journal: Dermatoendocrinol Date: 2016-05-16
Authors: Dina Angelika; Risa Etika; Muhammad Pradhika Mapindra; Martono Tri Utomo; Paulus Rahardjo; I Dewa Gede Ugrasena Journal: Ann Med Surg (Lond) Date: 2021-03-26
Authors: Dina Angelika; I Dewa Gede Ugrasena; Risa Etika; Paulus Rahardjo; Arend F Bos; Pieter J J Sauer Journal: Medicine (Baltimore) Date: 2021-05-07 Impact factor: 1.889